The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

Pfizer's new COVID vaccine shows promising results with 4x immunity boost, but Kennedy's restrictions leave most Americans ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its COVID-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to ...

Young people’s risk of developing myocarditis is higher and longer lasting after covid-19 infection than after vaccination against it, the largest study of its kind suggests.1 The research—based on ...

Despite hopes raised by Pfizer's COVID-19 vaccine, it will take huge efforts for India to defeat the coronavirus, with its ...

The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the ...

Some Alberta pharmacists say they've started waitlists for private COVID-19 vaccines because they can't get their hands on ...